Morningside Group

Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.

TypeInvestor
HQShanghai, CN
Founded1986
Websitemorningside.com
Morningside Group was founded in 1986 and is headquartered in Shanghai, CN

Viewing summary data as a guest

Sign up for free to see all data

Morningside Group Office Locations

Morningside Group has an office in Shanghai
Show all (1)

Morningside Group Online and Social Media Presence

Embed Graph

Morningside Group Blogs

TransThera Biosciences Lead Product TT-00420 Granted Orphan Drug Designation from FDA to Treat Cholangiocarcinoma

NANJING, China, Nov. 7, 2019 (PRNewswire) – TransThera Biosciences Co. Ltd, announced today that company received Orphan Drug Designation from US Food and Drug Administration (FDA) for TT-00420, a clinical stage investigational drug, for the treatment of cholangiocarcinoma. Dr. Frank Wu, Founder and…

Viken Unveils the Osprey Integrated Checkpoint SolutionTM for High Throughput Passenger & Commercial Vehicle Scanning at US Border Crossings

BURLINGTON, Mass., November 7, 2019 — (BUSINESS WIRE)–Viken Detection, pioneer of handheld x-ray imaging and analytical devices, today announced an award to install four Osprey-UVXTM under vehicle x-ray inspection systems at select U.S. Customs and Border Protection (CBP) land points of entry. The O…

Elysium Health™ Announces Head of Bioinformatics and the Launch of INDEX by Elysium Health

NEW YORK, Nov. 4, 2019 (PRNewswire) – Elysium Health, Inc.,TM a life sciences company developing clinically validated health products based on aging research, today announced the launch of INDEX by Elysium Health, an at-home test that enables customers to measure their cumulative rate of aging and t…

PhoreMost and Sentinel Oncology Expand Collaboration to Jointly Accelerate Novel Glioma Therapeutic Through Preclinical Development

CAMBRIDGE, England, November 4, 2019 (BUSINESS WIRE)–PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and Sentinel Oncology, today announce an expansion of their collaboration to accelerate the progression of SOL686, a novel allosteric Po…

Cambridge Startup Targets Alzheimer’s With A New Approach To An Old Idea

By Callum Borchers October 31, 2019 | WBUR.org – Recent efforts to treat Alzheimer’s disease have been marked by high hopes and major letdowns. Now, a Cambridge biotechnology startup called Pinteon is again raising hope — and millions of dollars — with what it touts as a new approach to an old idea.…

Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease

CAMBRIDGE, Mass., Oct. 31, 2019 – Pinteon Therapeutics today announced the launch of a Phase 1 trial of PNT001, a novel tau antibody that uniquely targets a toxic epitope known to drive neurodegenerative disease. Pinteon is funded by a $17 million Series A from Morningside Ventures and led by an exp…
Show more

Morningside Group Frequently Asked Questions

  • When was Morningside Group founded?

    Morningside Group was founded in 1986.

  • Where are Morningside Group offices?

    Morningside Group has an office in Shanghai.

  • How many offices does Morningside Group have?

    Morningside Group has 1 office.